

BOARD OF SUPERVISORS AGENDA ITEM REPORT CONTRACTS / AWARDS / GRANTS

⊜ Award	○ Contract	Grant	Requested Board Meeting Date:	June 22,	2021
---------	------------	-------------------------	-------------------------------	----------	------

* = Mandatory, information must be provided

or Procurement	Director Award	
----------------	----------------	--

*Contractor/Vendor Name/Grantor (DBA):

Department of Health and Human Services / Centers for Disease Control and Prevention (CDC)

*Project Title/Description:

Pima County Initiative to Address COVID-19 Health Disparities.

*Purpose:

Funding from this grant aims to expand existing and/or develop new mitigation and prevention resources and services to reduce COVID-19 related health disparities among populations at higher risk and that are underserved.

*Procurement Method:

This Revenue Contract is a non-Procurement contract and not subject to Procurement rules.

*Program Goals/Predicted Outcomes:

Activities to be funded include expanded testing and contact tracing strategies, including at-home testing and mobile testing; improve data collection and reporting for at risk populations; build, leverage and expand infrastructure support for COVID-19 prevention and control among target populations; implement evidence-based policies, systems, and environmental strategies to address COVID-19; create a sustainable Community Public Health Worker workforce; improve vaccine communications and community engagement; and create a health equity program tasked with building resilient communities.

*Public Benefit:

COVID-19 has disproportionately affected populations placed at higher risk and who are medically underserved, including racial and ethnic minority groups, and people living in rural communities who are at higher risk of exposure, infection, hospitalization, and mortality. Additionally, racial and ethnic minority groups and people living in rural communities have disproportionate rates of chronic diseases that increase the severity of COVID-19 infection and might experience barriers to accessing testing, treatment, or vaccination. This program will focus on these populations and seek to ensure that they have equal access to testing, contact tracing, vaccines, and other health care measures to reduce the disproportionate impact of the COVID-19 pandemic.

*Metrics Available to Measure Performance:

The work plan submitted as part of the PCHD proposal includes many strategies, activities and outputs to be accomplished with this funding. In addition, \$150,000 has been budgeted for evaluation and quality improvement activities.

*Retroactive:

Yes. The grant term begins June 1, 2021, the same day the notice of award was received. PCHD is requesting acceptance of this award be added to the Addendum for the next BOS meeting after the award was received. If not approved, PCHD will not be able to take advantage of this significant award to supplement our pandemic response.

CIMI Approved Wire 21 218 Revised 5/2020

Contract / Award Information			
Document Type:	Department Code:		Contract Number (i.e.,15-123):
Commencement Date:	Termination Date:		Prior Contract Number (Synergen/CMS):
Expense Amount: \$*			Revenue Amount: \$
*Funding Source(s) required:			
Funding from General Fund?	OYes No If Yes \$		%
Contract is fully or partially fund	ed with Federal Funds?	☐ Yes	□ No
If Yes, is the Contract to a ver	ndor or subrecipient?		
Were insurance or indemnity cla	auses modified?	☐ Yes	□ No
If Yes, attach Risk's approval.			
Vendor is using a Social Securit	ty Number?	☐ Yes	□ No
If Yes, attach the required form	per Administrative Procedure	22-10.	
Amendment / Revised Award	Information		
Document Type:			Contract Number (i.e.,15-123):
			ersion No.:
Commencement Date:			ermination Date:
			ontract No. (Synergen/CMS):
©Expense or ©Revenue	○Increase ○Decrease		t This Amendment: \$
Is there revenue included?	OYes ONo If		3
*Funding Source(s) required:		·	
Funding from General Fund?	OYes ONo If	Yes\$_	%
Grant/Amendment Informatio	n (for grants acceptance and	awards)	Award
Document Type: GTAW	Department Code: HD		Grant Number (i.e.,15-123): 21-174
Commencement Date: 06/01/202	.1 Termination Date: 0	05/31/202	3 Amendment Number: 00
☐ Match Amount: \$			enue Amount: \$ 6,510,503.00
	ed: Department of Health and H	_	vices / Centers for Disease Control and Prevention (CDC)
*Match funding from General	Fund? (Yes (No If)	Yes \$	0/ _A
*Match funding from other so			%
*Funding Source:	urces: Control of		, , , , , , , , , , , , , , , , , , , ,
*If Federal funds are received Federal government or passe			e No, directly from the CDC
Contact: Sharon Grant			
Department: Health			Telephone: 724-7842
Department Director Signature	e/Date:		6/11/21
Deputy County Administrator S	Signature/Date:	~_~	Src 15 June 2021
County Administrator Signatur		ila	ilietally Elistes
(Required for Board Agenda/Addendum I	tems)		/ ' '

Notice of Award

Award# 1 NH75OT000063-01-00

FAIN# NH75OT000063

Federal Award Date: 05/28/2021

Recipient Information

1. Recipient Name

Pima County Health Department 3950 S Country Club Rd Ste 100 Tucson, AZ 85714-2226 [NO DATA]

2. Congressional District of Recipient

- 3. Payment System Identifier (ID) 1866000543A2
- 4. Employer Identification Number (EIN) 866000543
- 5. Data Universal Numbering System (DUNS)
- 6. Recipient's Unique Entity Identifier

7. Project Director or Principal Investigator

Dr. Theresa Cullen Theresa.Cullen@pima.gov 520-724-7765

8. Authorized Official

Dr. Dorthee Harmon Division Manager, GMI dorthee.harmon@prima.gov 520-576-6067

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Mr. Dedrick Muhammad Grants Management Specialist qtm2@cdc.gov 678-475-4523

10.Program Official Contact Information

Ms. Christine Graaf khx2@cdc.gov 404-498-0442

Federal Award Information

11. Award Number

1 NH75OT000063-01-00

12. Unique Federal Award Identification Number (FAIN) NH75OT000063

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

Pima County Initiative to Address COVID-19 Health Disparities

15. Assistance Listing Number

93 391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public

17. Award Action Type

New

22. Offset

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date 06/01/2021 - End Date 05/31/2023

20. Total Amount of Federal Funds Obligated by this Action \$6,510,503.00 20a. Direct Cost Amount \$6,171,687.00 20b. Indirect Cost Amount \$338,816.00

21. Authorized Carryover \$0.00

\$0.00 23. Total Amount of Federal Funds Obligated this budget period \$0.00

24. Total Approved Cost Sharing or Matching, where applicable \$0.00 25. Total Federal and Non-Federal Approved this Budget Period \$6,510,503.00

26. Project Period Start Date 06/01/2021 - End Date 05/31/2023

27. Total Amount of the Federal Award including Approved

Cost Sharing or Matching this Project Period Not Available

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Shirley K Byrd Grants Management Officer

30. Remarks

APPRÓVEDAS TO FORM:

Deputy County Attorney

REVIEWED BY:

Appointing Authority or Designee Pima County Health Department

Page 1

Notice of Award

Award# 1 NH75OT000063-01-00

FAIN# NH75OT000063

Federal Award Date: 05/28/2021

Recipient Information

Recipient Name

Pima County Health Department 3950 S Country Club Rd Ste 100 Tucson, AZ 85714-2226 [NO DATA]

Congressional District of Recipient

03

Payment Account Number and Type

1866000543A2

Employer Identification Number (EIN) Data

866000543

Universal Numbering System (DUNS)

144733792

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Project Grant

32. Type of Award

Other

I. Financial Assistance from the Federal Award	ding Agency Only		
II. Total project costs including grant funds and all other financial participation			
a. Salaries and Wages	\$1,875,376.00		
b. Fringe Benefits	\$693,889.00		
c. TotalPersonnelCosts	\$2,569,265.00		
d. Equipment	\$0.00		
e. Supplies	\$91,840.00		
f. Travel	\$4,952.00		
g. Construction	\$0.00		
h. Other	\$347,107.00		
i. Contractual	\$3,158,523.00		

34. Accounting Classification Codes

_						
	FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
	1-9390H06	21NH75OT000063C5	OT	41.51	\$6,510,503.00	75-2122-0140

j. TOTAL DIRECT COSTS

I. TOTAL APPROVED BUDGET

k. INDIRECT COSTS

m. Federal Share

n. Non-Federal Share

33. Approved Budget

\$6,171,687.00

\$338,816.00

\$6,510,503.00

\$6,510,503.00

\$0.00



Award# 1 NH75OT000063-01-00

FAIN# NH75OT000063

Federal Award Date: 05/28/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Pima County Health Department

1 NH75OT000063-01-00

1. OT21-2103 Terms and Conditions

Recipient: Pima County Health Department

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-OT21-2103, entitled National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities, and application dated May 3, 2021, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of \$6,510,503 is approved for a two year performance and budget period, which is June 1, 2021 through May 31, 2023. All future funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS—CoV–2 or to diagnose a possible case of COVID–19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf. Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Pre-Award Costs: Pre-award costs dating back to March 15, 2021 – and directly related to the COVID-19 outbreak response are allowable.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs:

The recipient's indirect costs are approved and based on a de minimis rate of ten (10) percent of modified total direct costs (MTDC) as defined in 45 CFR Part 75.2, effective June 1, 2021.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Dedrick Muhammad, Grants Management Specialist
Centers for Disease Control and Prevention
Global Health Services Branch
2939 Flowers Road
Atlanta, GA 30341
Email: qtm2@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov.or.by.mail.to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

PROGRAM OR FUNDING SPECIFIC CLOSEOUT REQUIREMENTS

The final programmatic report format required is the following.

Final Performance Progress and Evaluation Report: This report should include the information specified in the NOFO and is submitted 90 days following the end of the period of performance via www.grantsolutions.gov. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

Additional guidance may be provided by the GMS and found at: https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of

recipients for business and administrative matters pertinent to grant awards.

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.